Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

88 Identification o IL-10

12th World AIDS Conference

Keyword

Abstract

-Keyword

Abstract

exual risk-taking?/Gay: Does it reduce or increase 60503
bgroups within group M identified with human monoclonal antibod 11164
bination of HIV-1 strains in China/Genetic recombination 429*/11179
ventions with non-gay men who have sex with men/Eff 14266
ell clonal dominance in HIV-infected children by CDR 212*/21106
Barriers to condom use by HIV infected and at-risk wom 23420
HIV-IEC Intervention to fun houses and illegally operatin 23548
phocyte (CTL) epitopes in studies of Thai HIV-infected fe 603*/31127
nce of Thailand/Needs by counselling staff in a souther 60997
m/Evaluation of unique identifiers:The Maryland non-named bas 60387
bases/Two methods to identify potential long-term non-progresso 13360
n HIV prevention and to research gaps/Gathering the evid 43524
of southern Myanmar/ Identifying HIV risk factors and informatio 14197
erence in pediatric HIV: the issues from providers and f 32438
r of a vulnerable group/ gaps in an behavioural interve 33297
ecting the unexpected: and reducing perceived occup 60364
he HIV/AIDS epidemic/ best practices, as the armed fo 60577
io de Janeiro, Brazil/ Identities and social organisation: An ethn 24102
ure/Vulnerability to HIV, identity and reproductive failure/Vulnerab 13576
Self-acceptance of gay decreases sexual risk behavior an 154*/14135
n gay social and sexual /Recreational drug use among ga 14180
g a future: Adopting the of a chronically ill person/From su 24263
dherence/Adult social is part of culturally competent HIV 32355
inal two-spirited sexual and HIV/AIDS/North American ab 34196
he emergence of "gay" and "gay" support groups in India/ 43337
control study of gender disorder and HIV disease/Case c 60177
n HIV care/The social and self-concept of HIV-positive tr 60309
exuals: Culture, gender ideology, and perceived risk/Determinant 14244
atment with cefixime on ideopathic mouth ulcers on patients with 22331
he West Midlands, UK/ Idiopathic CD4+ T-cell lymphocytopenia (I 32151
evalence monitoring in IDU, MSM, STD patients, and pregnancies 13189
n causing an explosive epidemic in Kaliningrad/HIV-1 genetic 13190
en in Europe/The male epidemic is closely linked to its second 13200
IV surveillance among recruited at 11 syringe exchange progr 23172

ntravenous drug users ( )/Implantation of public health strateg
ailure in patients using IDV-containing triple therapy/Low plasma
e study of d4T + 3TC + IDV versus ZDV + 3TC + IDV in treatment n
ve study of d4T + ddl + versus ZDV + 3TC + IDV in treatment n
-up of indinavir sulfate ( ) administered q 8 hours (q8H) versus q
4 cells/mm3/Indinavir ( ) in combination with zidovudine (ZDV)
navir with stavudine vs. alone vs. stavudine alone in zidovudin
udine (ZDV), indinavir ( ) and lamivudine (3TC) in HIV-1 infecte
bination with indinavir ( ) [DMP 266-003, Cohort IV]/Durable cli
enz (EFV) + indinavir ( ), versus EFV + zidovudine (ZDV) + la
apine (NVP), indinavir ( ), and lamivudine (3TC)/Sequence ana
MP 266) and indinavir ( ) versus indinavir in HIV-1 infected pati
nations with indinavir ( ), zidovudine (ZDV), lamivudine (3TC),
ns-combining indinavir ( ) with ritonavir (RTV): Results from first
s treated with indinavir ( )/Saliva as a possible specimen for mo
hips between indinavir ( ) pharmacokinetics and antiviral activit
sma levels of indinavir ( ) are highly predictive of virological trea
/Switch from indinavir ( ) to nelfinavir (NFV) in patients on antivi
n a study of indinavir ( ) alone and with zidovudine (ZDV) in tre
) regimens (d4T+3TC+ vs. d4T+RTV+SQV) in pre-treated pati
s treated with indinavir ( )/Hyperbilirubinemia in patients treate
4T + 3TC + indinavir ( )/Long-term follow-up of a cohort of 14
ng tritherapy including failure: Results on RNA viral load and
y of C6te d'lvoire/AIDS/ IEC in high schools and at the University of
n Tanzania/Alternative interventions for promoting behaviour
hment-based STD/HIV- Intervention to identified fun houses an
cation-communication ( ) among prostitutes registered with an
stern Nigeria/Impact of /Outreach programs on the prevention
ania/Outlining of a new strategy for Tanzania/Outlining of a ne
gy/Data organizing and development for overseas contract wo
d Forces/Interpersonal as a long-term strategy for the preventi
n and communication ( )/Innapropriate language as a barrier t
viewpoint - A project in Ife-ljesa zone, Osun State, Nigeria/Home
ums of Nairobi through IGA group processes/Empowerment of ne
neutralizing activity and IgA in exposed seronegative (ESN) partne
HIV-1 specific mucosal in a cohort of HIV-1 resistant Kenyan p
y derived HIV-1 specific antibodies/Characterization of salivar
nteractions of secretory with HIV-1 gp120: Potential pitfalls of a
tion/Characteristics of anti-HIV antibodies in plasma and saliv
izing effect of secretory to HIV in parotid saliva of HIV-infected
infected mothers/Total IgE levels in infants born from HIV infected
solates by HIV patient IgG directed to a viral-associated epitope/I
hailand/Detection of antibodies to HHV-8 in HIV-1 positive i
HIV1-negative children/ antibodies binding to CD4+ T-cells are
nti-HIV-1 agent/Human IgM monoclonal antibody to ganglioside G
angladesh: Potential for ignitable HIV epidemic/Injecting drug use
HIV/AIDS/Poverty and ignorance as principal factors in prevalenc
em failures: Abort, retry, ignore?/Solutions to system failures: Abor
on of specific anti-HIV-1 IgY produced in species pathogen free chi
perinatal transmission: IHO-Wadia model/Prevention of perinatal
apy: An update/Phase II study of ritonavir-nelfinavir combination t

60630
42275
12223
12225
12290
12311
12335
12357
12359
22336
22337
22343
22371
22372
512*/32330
42266
42275
60181
60358
60791
60808
60875
60966
13551
14287
23548
33310
33371
33471
33501
43398
43569
42423
60157
21124
329*/31101
31119
162*/41101
60587
60770
42112
31110
31192
42110
31112
23215
60757
60131
41239
23309
12207

le injecting drug users (
V-infection spreading in
y injection drug users (
s by injection drug use (
IDS prevention among
ds care for HIV infected

) in London, 1990 to 1996/HIV prevale
in Russian Federation/HIV-antibody t
)/Initial viral load (VL) soon after seroc
) after accounting for CD4+ count and v
in Geneva/The role of the police and p
patients/Attitude of French GPs towar

ction between women/ IDUS men's sexual risk behavior contributi
detoxification amongst IDUs and heroin users from the slums/Dru

of injecting drug users (
m injecting drug users (
ng injecting drug users (
ncidence in Vancouver
in injecting drug users (
by injecting drug users (
ntravenous drug users (
of injection drug users (
Risk behaviors among
two-city comparison of
se and discard among
evention for adolescent
ng injecting drug users (
try injecting drug users (
of HIV infection among
n with HTLV-I/II among
ng injecting drug users (
The AIDS cases among
rs among HIV-infected
nt injection drug users (
n perceptions of HIV(+)
with low infection rate in
ng injection drug users (
d injection drug users (
ng injecting drug users (
rough outreach among
munity mobilisation with
nt injection drug users (
to injecting drug users (
S in long-term surviving
- injection drug users (
HIV prevention among
ng injecting drug users (
HIV prevention among
AIDS prevention among
es/Vaccination among
ywood, CA/Adolescent
ion to the treatment for

) in Bangkok, Thailand/HIV-1 inciden
) in Bangkok, Thailand/Genetic chara
) in Bangkok, Thailand/Similar risk fa
during an outbreak of HIV infection/H
) newly infected with HIV-1 subtypes
) based on the analysis of blood trace
)against HIV infection?/Do A32 CCR
) in preparation for HIV vaccine effica
who give injections to or receive injec
' preparation practices/Viability of HI
in a city with a legal needle exchange
at a storefront needle exchange prog
)/Projeto Brasil-Rio De Janeiro, prev
): 1992-1996/Behaviours change's a
and natural history of HIV infection in
in Rio de Janeiro, Brazil/Prevalence
) along the US-Mexico border/The rol
in Brazil/The AIDS cases among
in France (cohort MANIF 2000)/Com
)/Health status and co-morbidity of HI
as barriers to treatment/Physician pe
and sex-workers/Unaddressed need
): Do mobile programs attract those at
)/Feasibility and willingness to partici
)- Creating a "setting"/Phase II: Atte
of Calcutta, India/Behavioural modifi
on Bangladesh/India border/Harm re
) into drug treatment: Effects on reduc
)/The harm reduction cards system:
/The CD38 subset of CD8 cells predi
)/A comparison of the Unmet service
in the town of Svetlogorsk, Gomel reg
)in Bangkok, Thailand/Willingness to
in Belarus/Mobilization of organizati
in Belarus/HIV/AIDS prevention amo: The role of economic incentives/Vac
' patterns of utilization of a storefront n
/The construction of the Brazilian mo

585*/23214
23225
23396
23456
33411
60338
23249
12413
13127
13133
13144
13296
191*/13302
14114
23180
23181
23189
23196
23200
23204
23208
23224
23244
23248
24103
24216
32359
503*/32409
32412
32437
33196
33214
33293
33338
408*/33386
33398
33418
42191
43304
43467
43548
44261
44299
60276
60545
60612

ected patients (START )/An open-label, randomized, comparativ 12225
ss I antigens and class alleles in Brazilian AIDS patients with cyt 22272
sarcoma (KS)/A phase study of oral thalidomide in patients with 22280
MP 266-005]/A phase,double-blind, placebo-controlled, dose r 22334
MP 266-006]/A phase, multicenter, randomized, open-label stu 22336
cted patients/A phase randomized open label study of adefovir 22371
acterization in a phase, open-label, multicenter study at 24 week 22386
dulator WF10 (A phase pathogenesis study)/Immunological par 22417
mized, controlled phase trial of S.C. interleukin-2 in HIV patients/ 22420
ion in Uganda/Phase I/ trial of HIVIG for the prevention of HIV-1 v 22422
o-infection with HTLV-I/ among IDUs in Rio de Janeiro, Brazil/Pre 23248
ating a "setting"/Phase: Attending injecting drug users (IDUs) - 33293
Health Study (REACH )/Changing patterns in injection practices 33394
of Vironostika Uni-Form plus O with samples from Thailand/Sensi 41117
d their infants/Phase I/ study of single dose nevirapine in HIV inf 41131
se inhibitor, in a phase I/ study/The safety, tolerance, pharmacoki 293*/41176
Anti-HIV-1/2 EIA DAGS: A highly sensitive assay based entirely o 42108
tiviral activity in phase I/ trials/Relationships between indinavir (I 42266
ning Councils and Title Care Consortia/Self-assessment modul 44310
a/Prevalence of HTLV-I/ infections in different populations group i 60108
ed, single-blind, phase Ila study of lenograstim (rHuG-CSF) to allo 32146
seases "Emilio Ribas" ( IIER ), Sao Paulo, SP, Brazil/AIDS mortalit 60580
n relationship in Phase III study of nelfinavir mesylate (Viracept~)/ 12304
MP 266-020]/A phase,double-blind, placebo-controlled, multic 22343
n PACTG 316: A phase randomized, blinded study of single-dos 23281
y of abacavir in a phase pediatric study/Correlation of phenotypi 232*/32283
ents enrolled in a phase clinical trial/Population pharmacokinetic 42267
ent outcome in a phase trial of buprenorphine-naloxone opiate d 42325
nsmission?/Increased IL-10 in the endocervix of women with STD 13280